Redeye provides a research update following the Q2 report recently published by AlzeCure. The report, much like the quarter as a whole, was largely characterized by the two historic deals for Alzstatin and NeuroRestore, with Eli Lilly and QuantumCell, respectively. Additionally, the quarter also saw encouraging progress in the company's pain projects ACD440 and ACD137 (TrkA-NAM), with the former being granted orphan drug designation and the latter showcasing significant pain relief and anti-inflammatory effect in newly published preclinical data. Following Redeye's new valuation approach, which factors in both fundamental valuation and relative valuation, we assign AlzeCure a new fair value of SEK13 per share.
LÄS MER
